Evropská unie - švédština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ozanimod hydroklorid - multiple sclerosis, relapsing-remitting; colitis, ulcerative - immunsuppressiva - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Evropská unie - švédština - EMA (European Medicines Agency)

orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - andra nervsystemet droger - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still  have the ability to walk independently and before the onset of cognitive decline.

Evropská unie - švédština - EMA (European Medicines Agency)

janssen-cilag international n.v.    - ponesimod - multipel skleros, skovvis förlöpande - immunsuppressiva - ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Evropská unie - švédština - EMA (European Medicines Agency)

sandoz gmbh - epoetin alfa - anemia; kidney failure, chronic - antianemiska preparat - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. hjärt-status, pre-existerande anemi vid start av kemoterapi).

Evropská unie - švédština - EMA (European Medicines Agency)

hexal ag - epoetin alfa - anemia; kidney failure, chronic; cancer - antianemiska preparat - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. behandling av anemi och reducering av transfusion krav hos vuxna patienter som får kemoterapi för solida tumörer, malignt lymfom eller multipelt myelom, och vid risk för transfusion enligt bedömning av patientens allmänna status (e. hjärt-status, pre-existerande anemi vid start av kemoterapi).

Evropská unie - švédština - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. se avsnitt 4. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Evropská unie - švédština - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - immunsuppressiva - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Evropská unie - švédština - EMA (European Medicines Agency)

virbac s.a. - rekombinant omega-interferon av felint ursprung - immunstimulatorer, - dogs; cats - dogsreduction of mortality and clinical signs of parvovirosis (enteric form) in dogs from one month of age. catstreatment of cats infected with feline leukaemia virus (felv) and / or feline immunodeficiency virus (fiv), in non-terminal clinical stages, from the age of nine weeks. in a field study conducted, it was observed that there was:a reduction of clinical signs during the symptomatic phase (four months);a reduction of mortality:in anaemic cats, mortality rate of about 60% at four, six, nine and 12 months was reduced by approximately 30% following treatment with interferon;in non-anaemic cats, mortality rate of 50% in cats infected by felv was reduced by 20% following treatment with interferon. hos katter infekterade av fiv var mortaliteten låg (5%) och påverkades inte av behandlingen.

Evropská unie - švédština - EMA (European Medicines Agency)

zentiva k.s. - riluzole - amyotrofisk lateral skleros - andra nervsystemet droger - riluzole zentiva är indicerat för att förlänga livet eller tiden för mekanisk ventilation för patienter med amyotrofisk lateralskleros (als). clinical trials have demonstrated that riluzole zentiva extends survival for patients with als. Överlevnad definieras som patienter som var vid liv, inte intubated för mekanisk ventilation och trakeostomi-gratis. det finns inga bevis för att riluzole zentiva har en terapeutisk effekt på motorisk funktion, lungfunktion, fascikulationer, muskelstyrka och motoriska symtom. riluzole zentiva har inte visat sig vara effektiva i sena stadier av als. säkerhet och effekt av riluzole zentiva har endast studerats i als. därför riluzole zentiva bör inte användas hos patienter med någon annan form av motoriska neuroner sjukdom.

Evropská unie - švédština - EMA (European Medicines Agency)

zoetis belgium sa - oclacitinibmaleat - agenter för dermatit, med undantag av kortikosteroider - hundar - - treatment of pruritus associated with allergic dermatitis in dogs. - treatment of clinical manifestations of atopic dermatitis in dogs.